Immunotec Wins Gold Globee Awards for Global Growth and Innovation
News related to:Immunotec · 2 min read
Immunotec, a global health and wellness company, has been recognized with two Gold Globee® Awards, including Best of Category honors for Global Growth and Immunocal® Innovation. These accolades highlight the company's achievements in both rapid expansion and scientific innovation.
In the category of Achievement in Rapid Growth & Scaling, Immunotec was awarded a Gold Globee® for its ability to accelerate global growth while maintaining profitability. The company expanded its annual revenue from approximately $145 million in 2023 to $200 million in 2025. During this period, earnings before interest, taxes, depreciation, and amortization (EBITDA) grew from approximately $10 million to nearly $25 million, demonstrating the company's capability to translate revenue growth into stronger profitability.
The company's success has never been about growth alone. It's about building a stronger company, continuing to advance the research behind Immunocal and creating lasting value for the people and communities it serves.
Immunotec's second Gold Globee® Award recognized its flagship product, Immunocal®, in the HealthTech, Life Sciences or Biotech Product or Service of the Year category. Immunocal has been at the center of Immunotec's scientific mission for approximately 30 years, supported by ongoing research into cysteine delivery, glutathione production, and cellular health. The product's scientific foundation is bolstered by more than 90 scientific publications and 26 blinded human clinical trials. Immunotec has also continued to advance its intellectual property portfolio through research and patented innovations involving Immunocal and related scientific applications.
Immunocal has established a significant global presence, contributing to Immunotec's delivery of more than 10 million boxes of Immunocal to customers worldwide over the past five years.
Today, Immunotec operates in 31 markets worldwide, including North America, Latin America, and Europe, with recent expansion into Asia. The company's global presence and financial foundation position it to pursue new opportunities while investing in the continued growth of its established markets. Under a disciplined growth strategy, Immunotec increased annual revenue from approximately $145 million in 2023 to $200 million in 2025. During that same period, EBITDA grew from approximately $10 million to nearly $25 million, demonstrating the company's ability to translate revenue growth into stronger profitability.
These awards reflect Immunotec's approach to building a company where scientific innovation and business performance reinforce one another. As the company continues to expand its international presence, it remains focused on strengthening its operations, supporting its global community, and investing in research that advances its product portfolio.